Contrast sensitivity visual acuity in REM sleep behavior disorder: a comparison with and without Parkinson disease

Whitfield, Whitney H; Barr, Garrett; Khayata, Matthew; Vogt, Peggy; Keasler, Eric; Sánchez, Jacqueline; Zhang, Song; Dieujuste, Marvin; Cardon, Brandon; Riggs, Ryan; Pique, Karina; Merin, Elliot; Huang, David; Maitland, Charles G.

doi:10.5664/jcsm.8212

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent small study, the visual acuity and the contrast sensitivity of 12 iRBD has been found to be reduced compared to controls, and further declined after a one-year follow-up [ 67 ]. Further tests would be needed to assess whether this could constitute a possible marker of progression in iRBD.…”

Section: Clinical Markers Of Progressionmentioning

confidence: 99%

Predictors of RBD progression and conversion to synucleinopathies

Natale

Wilson

Politis

2022

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Purpose of review Rapid eye movement (REM) sleep behaviour disorder (RBD) is considered the expression of the initial neurodegenerative process underlying synucleinopathies and constitutes the most important marker of their prodromal phase. This article reviews recent research from longitudinal research studies in isolated RBD (iRBD) aiming to describe the most promising progression biomarkers of iRBD and to delineate the current knowledge on the level of prediction of future outcome in iRBD patients at diagnosis. Recent findings Longitudinal studies revealed the potential value of a variety of biomarkers, including clinical markers of motor, autonomic, cognitive, and olfactory symptoms, neurophysiological markers such as REM sleep without atonia and electroencephalography, genetic and epigenetic markers, cerebrospinal fluid and serum markers, and neuroimaging markers to track the progression and predict phenoconversion. To-date the most promising neuroimaging biomarker in iRBD to aid the prediction of phenoconversion is striatal presynaptic striatal dopaminergic dysfunction. Summary There is a variety of potential biomarkers for monitoring disease progression and predicting iRBD conversion into synucleinopathies. A combined multimodal biomarker model could offer a more sensitive and specific tool. Further longitudinal studies are warranted to iRBD as a high-risk population for early neuroprotective interventions and disease-modifying therapies.

show abstract

Section: Clinical Markers Of Progressionmentioning

confidence: 99%